



**HAL**  
open science

# Interactions between the nucleoprotein and the phosphoprotein of pneumoviruses: structural insight for rational design of antivirals

Hortense Decool, Lorène Gonnin, Irina Gutsche, Christina Sizun,  
Jean-François Eléouët, Marie Galloux

## ► To cite this version:

Hortense Decool, Lorène Gonnin, Irina Gutsche, Christina Sizun, Jean-François Eléouët, et al.. Interactions between the nucleoprotein and the phosphoprotein of pneumoviruses: structural insight for rational design of antivirals. *Viruses*, 2021, 13 (12), pp.2449. 10.3390/v13122449 . hal-03520624

**HAL Id: hal-03520624**

**<https://hal.science/hal-03520624v1>**

Submitted on 11 Jan 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.




L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Review

# Interactions between the Nucleoprotein and the Phosphoprotein of Pneumoviruses: Structural Insight for Rational Design of Antivirals

Hortense Decool<sup>1,†</sup>, Lorene Gonnin<sup>1,†</sup>, Irina Gutsche<sup>2</sup>, Christina Sizun<sup>3</sup>, Jean-François Eléouët<sup>1,\*</sup> and Marie Galloux<sup>1,\*</sup>

<sup>1</sup> IM, UVSQ, INRAE, Université Paris-Saclay, 78350 Jouy-en-Josas, France; hortense.decool@inrae.fr (H.D.); lorene.gonnin@inrae.fr (L.G.)

<sup>2</sup> IBS, CEA, CNRS, University of Grenoble Alpes, 38044 Grenoble, France; irina.gutsche@ibs.fr

<sup>3</sup> Institut de Chimie des Substances Naturelles, CNRS, Université Paris-Saclay, 91190 Gif-sur-Yvette, France; christina.sizun@cnrs.fr

\* Correspondence: jean-francois.eleouet@inrae.fr (J.-F.E.); marie.galloux@inrae.fr (M.G.)

† These authors contributed equally to this work.

**Abstract:** Pneumoviruses include pathogenic human and animal viruses, the most known and studied being the human respiratory syncytial virus (hRSV) and the metapneumovirus (hMPV), which are the major cause of severe acute respiratory tract illness in young children worldwide, and main pathogens infecting elderly and immune-compromised people. The transcription and replication of these viruses take place in specific cytoplasmic inclusions called inclusion bodies (IBs). These activities depend on viral polymerase L, associated with its cofactor phosphoprotein P, for the recognition of the viral RNA genome encapsidated by the nucleoprotein N, forming the nucleocapsid (NC). The polymerase activities rely on diverse transient protein-protein interactions orchestrated by P playing the hub role. Among these interactions, P interacts with the NC to recruit L to the genome. The P protein also plays the role of chaperone to maintain the neosynthesized N monomeric and RNA-free (called N<sup>0</sup>) before specific encapsidation of the viral genome and antigenome. This review aims at giving an overview of recent structural information obtained for hRSV and hMPV P, N, and more specifically for P-NC and N<sup>0</sup>-P complexes that pave the way for the rational design of new antivirals against those viruses.

**Keywords:** pneumoviruses; RSV; HMPV; nucleoprotein; phosphoprotein; protein-protein interaction; structure; antivirals; nucleocapsid



**Citation:** Decool, H.; Gonnin, L.; Gutsche, I.; Sizun, C.; Eléouët, J.-F.; Galloux, M. Interactions between the Nucleoprotein and the Phosphoprotein of Pneumoviruses: Structural Insight for Rational Design of Antivirals. *Viruses* **2021**, *13*, 2449. <https://doi.org/10.3390/v13122449>

Academic Editor: Akira Ono

Received: 30 October 2021

Accepted: 1 December 2021

Published: 6 December 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. The *Pneumoviridae* Family

Pneumoviruses belong to the *Mononegavirales* order that includes many pathogenic human or animal viruses in 11 families, such as respiratory syncytial virus (RSV), metapneumovirus (MPV), Measles, Mumps, Rabies, Nipah, Ebola, and Vesicular stomatitis viruses (VSV) [1]. *Mononegavirales* have a non-segmented negative-sense RNA genome ranging from 13.2 to 15.3 kb. They form a large group exhibiting common genome organization and sharing similar replication mechanisms. Recently, the former paramyxoviral subfamily *Pneumovirinae* was elevated to family status *Pneumoviridae* [2]. This “new” family is composed of the two genera, *Metapneumovirus* and *Orthopneumovirus* (Table 1) [3].

The *Metapneumovirus* genus includes human metapneumovirus (hMPV) and avian metapneumovirus (aMPV). The *Orthopneumovirus* genus groups human respiratory syncytial virus (hRSV), bovine respiratory syncytial virus (bRSV), and pneumonia virus of mice (PVM). Although unclassified by the International Committee on Taxonomy of Viruses (ICTV), this taxon also includes ovine respiratory syncytial virus (ORV) and canine pneumovirus (CPV). More recently, an eighth pneumovirus was identified by metagenomic

sequencing of pooled nasal swabs in feral swine in the USA [4]. This newly identified *Orthopneumovirus* shows 93% and 91% protein identities with PVM and CPV, respectively, and was named swine orthopneumovirus (SOV). Amino acid sequence identities between nucleoproteins of SOV and other pneumoviruses are 59.8% for hRSV, 60% for bRSV, 45.7% for hMPV, and 43.3% for aMPV, respectively, indicating that the PVM/SOV group is distinct from *Meta-* and *Ortho-pneumoviruses* and could constitute a third genus.

**Table 1.** Phylogeny of *Pneumoviridae*.

Family	Genus	Viruses
<i>Pneumoviridae</i>	<i>Metapneumovirus</i>	Human metapneumovirus (hMPV) Avian metapneumovirus (aMPV)
	<i>Orthopneumovirus</i> *	Human respiratory syncytial virus (hRSV) Bovine respiratory syncytial virus (bRSV) Pneumonia virus of mice (PVM)

\* Unclassified viruses: Ovine respiratory syncytial virus (ORV), Canine pneumovirus (CPV), Swine orthopneumovirus (SOV).

## 2. Impact of Infections by *Pneumoviridae*

Viruses belonging to the *Pneumoviridae* family cause severe respiratory diseases in humans and animals. Among them, hRSV and hMPV are the main cause of bronchiolitis and pneumonia in young children (<5 years) [5–8]. hRSV infects nearly 100% of children in the first three years of life and is one of the principal causes of child hospitalizations. Worldwide, hRSV is estimated to be responsible for ~33 million acute lower respiratory infections (ALRI), resulting in more than 3.2 million ALRI-related hospitalizations and 118,200 deaths in children under 5 years [9]. In a recent systemic multisite study, hRSV was shown to be the first etiological agent responsible for severe pneumonia (more than 30%) in hospitalized children in Asia and Africa [10]. It is noteworthy that hRSV is also a frequent cause of otitis in infants [11] and that children who suffer from severe hRSV infection are at risk of developing further respiratory complications such as asthma [12].

After hRSV, hMPV is considered the second most common cause of ALRI in young children [7,8,13]. Isolated in 2001 in the Netherlands [14], it is thought to have derived from avian metapneumovirus (aMPV) subgroup C, 200 years ago [15]. The peak age of hospitalization for infants infected by hMPV occurs between 6–12 months, slightly later than the peak of hRSV, which is around 2–3 months. The clinical features and severity of hMPV are similar to those of hRSV. Furthermore, hRSV and hMPV are now recognized as being responsible for significant morbidity and mortality in elderly and immunocompromised persons, such as bone marrow transplant patients (with comparable disease burden to influenza) [16–20]. These viruses are seasonal, the peak of infection typically extending from early fall to early spring. In 2020, the emergence of coronavirus disease (COVID-19) triggered the large-scale implementation of non-pharmaceutical interventions such as confinement, mask-wearing, and extensive handwashing [21]. These preventive public health measures have had an impact on the circulation of diverse pathogens, specifically hRSV, as evidenced by the interseasonal epidemics of hRSV in several countries of the southern hemisphere and late epidemics of hRSV in the USA, Japan, and several European countries [22–25]. For example, the 2020–2021 bronchiolitis epidemic in mainland France lasted 15 weeks, comparable to the previous season, but with a delayed peak, 13 weeks later than that of the previous season, with a much lower amplitude. The proportion of hospitalizations for bronchiolitis has been comparable to that of recent seasons, but notable features of the 2020/21 season were a decrease in the proportion of cases over 65 years of age and an increase in the proportion of cases in children over 3 months and up to 5 years. In addition to the resurgence of hRSV and hMPV infections since March 2021, data indicate more severe illness in younger infants, possibly because of reduced immunity due to lack of exposure to these viruses in the previous season.

Finally, the *Pneumoviridae* family is also an important threat for livestock farming and has a strong economic impact, bRSV, and aMPV causing severe respiratory diseases in calves and poultry, respectively [26,27]. These infections are responsible for important animals' morbidity, leading to high mortality rates, mainly due to opportunistic infections by other viruses or bacteria [28,29]. To limit this, the current care consists of antibiotic administration during epidemics, which represents an indirect risk for animal and human health due to the emergence of resistant bacteria. In addition, the discovery of SOV in the USA suggests that yet unknown pneumoviruses could be responsible for respiratory diseases in other animal species. A recent study suggested a high prevalence of this virus in France [30]. However, further studies are required to determine whether this virus is pathogenic for pigs.


### 3. Treatments against Pneumoviruses

No vaccine is available against hRSV and hMPV. Although several vaccines against bRSV and aMPV are commercialized, their efficacy remains limited [27,31–34]. In this context, the development of antiviral drugs with a wide spectrum represents an alternative to human vaccination. This is especially true because vaccine development against hRSV and hMPV is hampered by the fact that these viruses mostly infect infants who have an immature immune system. Furthermore, as hRSV is 80% fatal to immunocompromised and transplanted patients and a significant cause of death in the elderly, the elaboration of antiviral strategies is a recognized necessity. So far, no specific inhibitors are commercially available against these viruses, ribavirin being used only exceptionally because of its toxicity and poor efficiency. A humanized monoclonal antibody directed against the surface fusion F glycoprotein (palivizumab Synagis®) is also available as a preventive treatment, but its efficiency is limited ( $\approx 50\%$ ), and its high cost restricts its use to high-risk infants [35]. Approximately 6000 children are treated with Synagis each year in France, with a cost of EUR 8000 per child (five injections). There is, therefore, a need for new and cheaper treatments, which implies the critical necessity to better understand the molecular mechanisms of virus replication. To date, most developed antiviral strategies aim at targeting the F protein to impair virus entry [36–39]. The viral polymerase L that is responsible for the enzymatic activities required for viral replication and transcription is the second main target of interest [40,41]. Among the developed compounds, the two fusion inhibitors, GS-5806 and JNJ-53718678, and the polymerase inhibitor ALS-008176, have been tested in humans [38,40,42]. However, the results of phase 2b trials of GS-5806 were disappointing [43,44], and clinical trials of ALS-008176 have recently been halted. The emergence of escape mutants upon treatment represents the main restriction and highlights the necessity to identify new targets and to associate different compounds. The functioning of the viral polymerase depends on different highly conserved transient protein-protein interactions (PPIs) that have no counterparts in cells. These viral PPIs being transient and of low affinity, molecules of high affinity that could compete with them may represent a new class of inhibitors. Furthermore, these interactions are now structurally well-characterized, allowing the rational structure-based design of antivirals.

### 4. Virions and Viral Cycle

Pneumoviruses are enveloped viruses, the virions having pleomorphic but mostly filamentous shapes [45–47]. Their genomes contain 8 to 10 genes that encode 9 and 11 proteins in the case of MPV and RSV, respectively (Figure 1A). The two non-structural proteins NS1 and NS2 of RSV, which are involved in the control of antiviral pathways during infection [48,49], have no counterparts in MPV. The virions present three transmembrane proteins: the glycoprotein (G) involved in virion attachment to the cell surface, the fusion (F) protein responsible for receptor binding and fusion between viral and cellular membranes, and the small hydrophobic protein (SH), a viroporin whose immunomodulatory role still remains unclear [50–52] (Figure 1B). The inner side of the viral membrane is lined by the matrix (M) protein. The viral particles contain the genomic RNA encapsidated

by the N protein, forming the nucleocapsid (NC), which is associated with the P-L-M2-1 proteins.




**Figure 1.** *Pneumoviridae* genomes and virion. **(A)** Genome organization of representative members of the *Pneumoviridae* family. Genomic RNAs are presented in sense (coding) orientation (3'-to-5'), with each box representing a gene encoding a separate mRNA drawn approximately to scale. The M2 gene encodes M1-2 and M2-2 proteins (represented by rectangles above M2 gene). **(B)** Representation of pneumovirus viral particle showing the structural proteins. Created with BioRender.com.

After fusion of the viral envelope with the cell membrane, the viral NC penetrates into the cytoplasm, where viral RNA transcription and replication occur (Figure 2). The viral RNA-dependent RNA polymerase (RdRp) L, associated with its cofactor P, is responsible for both activities [5,53]. Transcription of RSV also requires the viral protein M2-1, which acts as an anti-terminator/elongation factor [54,55], whereas MPV M2-1 is not essential for virus replication in cell culture [56]. During transcription, the RdRp has all the activities to transcribe, cap, and poly-adenylate mRNAs. Amplification of the viral genome by the RdRp necessitates the synthesis of an antigenome, which is also encapsidated by N. At the final stage of the viral cycle, NCs assemble with the other structural viral proteins at the cell surface to generate new virions (Figure 2).

More specifically, viral replication and transcription take place in cytoplasmic inclusions bodies (IBs), where all the proteins required for the activities of the RdRp concentrate [57] (Figure 2). These structures, also observed for others *Mononegavirales*, are membrane-less organelles that present liquid-like properties [58,59], and expression of N and P was shown to be sufficient to induce the formation of pseudo-IBs [60,61]. These IBs contain dynamic sub-compartments called IBAGs (IB-associated granules), where viral mRNA and the transcription factor M2-1 specifically accumulate [57] (Figure 2). It is noteworthy that hRSV proteins NS2 and M were also shown to localize to IBs [62–64]. Furthermore, different cellular proteins such as HSP70, actin, actin-associated proteins, translation initiation factors PABP, and eIF4G, as well as the phosphatase PP1, were shown to be recruited to IBs [57,65,66]. In particular, N was shown to interact with proteins involved in innate immune pathways such as MAVS, MDA5, and more recently, the subunit p65 of NF- $\kappa$ B, leading to their sequestration into IBs [67,68]. Thus, there is accumulating evidence that IBs are complex organelles that play a central role in the viral cycle, not

only for viral RNA synthesis but also as platforms for the traffic of NCs from IBs to the plasma membrane and for assembly, as well as in the regulation of cellular innate immune responses to infection.




**Figure 2.** Schematic representation of the viral cycle of Pneumoviruses. Virion attachment to the cell is mediated by F and G proteins. The F protein is responsible for the fusion of viral and cell membranes, leading to the delivery in the cytoplasm of the NC complexed with L, P, and M2-1 proteins. Transcription and replication occur in membrane-less organelles called cytoplasmic inclusion bodies (IBs, light brown). Within IBs, M2-1 and viral mRNAs accumulate into sub-structures called inclusion body-associated granules (IBAGs, yellow). After viral protein production and genome replication, assembly and budding of new viral particles take place at the plasma membrane. Adapted from “Replication Cycle”, by BioRender.com (2020). Retrieved from <https://app.biorender.com/biorender-templates> (30 November 2021).

## 5. The Replication/Transcription Machinery of Pneumoviruses

The RdRp functioning depends on different PPIs, with the phosphoprotein P acting as a hub to recruit many partners, and more particularly by interacting with NC, L, M2-1, and the neosynthesized N ( $N^0$ ) (Figure 3).

The last decades were marked by the accumulation of structural and functional information on the pneumoviral RdRp. The main achievement was the recent determination of the 3D structure, although partial, of the L-P complexes of hRSV and hMPV by cryo-electron microscopy [69,70]. These structures revealed strong structural conservation between these two complexes, with a particular mode of P binding to L (see Section 6.1). They allowed establishing a model for the spatial functioning of L [70]. The structure and activities of the L protein will not be discussed extensively here. Briefly, the RdRp recognizes and uses the viral RNA genome as a template exclusively when it is encapsidated by N inside a flexible helical NC (Figure 3). This recognition is mediated by P, which is essential for loading the L polymerase onto the NC template and for keeping it bound to its template in a dynamic fashion during RNA synthesis.



**Figure 3.** Schematic representation of the polymerase functioning of pneumoviruses. The polymerase L is responsible for both viral replication and transcription. The P protein plays a role in the hub by interacting with L and NC through its C-terminal P<sub>CTD</sub> domain and with M2-1 and the monomeric and RNA-free N (N<sup>0</sup>) through its N-terminal P<sub>NTD</sub> domain. Created with BioRender.com (30 November 2021).


The L protein embeds all enzymatic activities required for replication and transcription. The L protein contains an RdRp domain followed by a polyribonucleotidyl-transferase domain (PRNTase or capping domain) and a methyltransferase (MTase) domain. During transcription, the L protein scans the viral RNA, and mRNA synthesis begins at a conserved gene start sequence (GS). When the RNA is about 30 nucleotides long, a GMP moiety, covalently linked to the PRNTase domain of L, is transferred to the 5' end of the nascent viral RNA, forming a cap structure (GpppG-RNA). The cap is subsequently methylated on its 2' O and N7 position (N7GpppGm-RNA) by the MTase activity of L [71]. It is noteworthy that, although the mechanism still remains poorly understood, efficient hRSV transcription requires the recruitment of the M2-1 protein by P [54,55]. During replication, the RdRp synthesises antigenomes and genomes that are concomitantly encapsidated by the N protein. The assembly of new functional viral genomes requires a continuous supply of unassembled N molecules (N<sup>0</sup>). The P protein is an essential co-factor in this process by forming an N<sup>0</sup>-P complex to maintain N in a competent form for the encapsidation of new viral genomes (Figure 3).

## 6. Insights into P and N Protein Structures

The P and N proteins are the two main actors of the polymerase complex. Besides their direct role in viral RNA synthesis, they were shown to be the scaffold proteins responsible for IB morphogenesis [61,72]. This architectural role of P and N for IB formation was recently shown to depend on a liquid-liquid phase separation (LLPS) mechanism, requiring N-P interaction [73]. The LLPS mechanism is now well characterized. It is initiated by scaffold molecules that form condensates through the establishment of a network of interactions, more frequently, proteins and RNA. The archetype of protein architecture sustaining the formation of the LLPS relies on proteins with intrinsically disordered regions (IDRs) presenting multiple interacting motifs of low affinity [74–76] and RNA-interacting domains. The pneumoviruses P proteins, which present different IDRs and interact with NC, appear to be the pivotal element for IB morphogenesis [73].

### 6.1. The Modular Structure of the Phosphoprotein P

Pneumoviral P proteins play a central role during the virus cycle, their high plasticity allowing the establishment of transient and complex interactions with various partners. Both hRSV and hMPV P proteins (of 241 and 294 residues, respectively) form parallel tetramers with a central oligomerization domain ( $P_{OD}$ ) consisting of a helical coiled-coil core, flanked by two intrinsically disordered regions ( $P_{NTD}$  and  $P_{CTD}$ ) (Figure 4A) [77–81]. Sequence alignment of the hRSV and hMPV phosphoproteins indicates a sequence identity and similarity of 28% and 38%, respectively, as calculated with the Sequence Manipulation Suite using an alignment made on the T-coffee server [82].  $P_{OD}$  displays very high conservation with 65% identity and 80% similarity between hRSV and hMPV.  $P_{C\alpha}$ , a subdomain of  $P_{CTD}$  with a high helical propensity, has 41% identity and 52% similarity. The  $P_{NTD}$  domain is longer in hMPV P than in hRSV P, but the N-terminus and the region proximal to the oligomerization domain also present conserved motifs that are likely molecular recognition elements (Figure 4A).



**Figure 4.** Structure of Pneumovirus P proteins. (A) Domain architecture of hRSV and hMPV P proteins, with a fully disordered N-terminal domain,  $P_{NTD}$ , a short tetrameric coiled-coil oligomerization domain,  $P_{OD}$  (blue), and a C-terminal domain,  $P_{CTD}$ , consisting of a domain with a high  $\alpha$ -helical propensity,  $P_{C\alpha}$  (red), and a highly disordered C-terminal tail,  $P_{Ctail}$ . The interaction regions of hRSV P with RdRp, or associated proteins like PP1, are indicated by arrows and bold lines. The corresponding regions in hMPV are also in bold lines. (B) High-resolution cryo-EM structures of the tetrameric L-associated hRSV and hMPV P proteins. Only the  $P_{OD}$  and  $P_{C\alpha}$  domains are observed in the L-P complex structures. Neither  $P_{NTD}$  nor  $P_{Ctail}$ , except for a single protomer, could be observed due to high disorder. Created with Pymol (<https://pymol.org>, 30 November 2021).

NMR proved to be a well-suited tool to obtain structural data of hRSV P alone in solution, and of its intrinsically disordered domains, in particular. This revealed that although these domains were not stably folded, several regions of  $P_{NTD}$  and  $P_{CTD}$  presented a propensity to form transient  $\alpha$ -helices, likely to be involved in various PPIs [83–85]. These




results were confirmed by interaction studies between P and N or M2-1 [65,83,86], but also by resolution of the 3D structures of P fragments in the complex with N<sup>0</sup> [87], M2-1 [88], and L [69,70]. Whereas the interactions with N<sup>0</sup> and M2-1 were shown to involve short linear motifs of the P<sub>NTD</sub> domain that fold into helices upon binding, the recent structures of L-P complexes revealed that both P<sub>OD</sub> and P<sub>CTD</sub>, the latter mostly through P<sub>Cα</sub>, interacts with L [69]. The location of these binding sites is indicated in Figure 4A. Interestingly, each P<sub>CTD</sub> in the P tetramer was shown to adopt a specific and different conformation in contact with L (Figure 4B). However, the conformation of the L-bound hRSV and hMPV P<sub>CTD</sub> tetramers is strikingly similar: structural alignment yields an RMSD of 1.224 Å. Of note, a recent study revealed that the hRSV P-M interaction involves both P<sub>NTD</sub> and P<sub>OD</sub> [64]. In contrast to these extended binding regions, the linear sequence corresponding to the last C-terminal residues of P was shown to be sufficient for binding to NC [89–91].

It is noteworthy that major and minor sites of phosphorylation were identified on hRSV P, with two main clusters of phosphorylated serines S116/S117/S119 and S232/ S237 [92,93]. The phosphorylation status of P was shown to depend on cellular casein kinase II [94] and phosphatases PP1 and PP2A [93]. Although the role of these post-translational modifications during replication and transcription remains unclear [95–97], phosphorylation of hRSV P was shown to regulate its interaction with N and M2-1 [65,93,96,98]. hRSV P protein was also shown to recruit the phosphatase PP1 to IBs [65]. This interaction involves an RVxF-like motif of P located nearby and upstream of the M2-1 binding region (Figure 4A), which is conserved in hMPV P. Through its interaction with hRSV P, PP1 is involved in M2-1 dephosphorylation required for the efficient functioning of M2-1 and viral transcription. Therefore, phosphorylation is critical for the regulation of PPIs within the polymerase complex and efficient functioning.

## 6.2. Structure of Nucleoproteins

The N protein, which is responsible for genome and antigenome encapsidation, is composed of 391 and 394 residues for hRSV and hMPV, respectively. This protein has a high binding affinity for RNA coupled with a strong tendency to oligomerize. The 3D crystal structure of the hRSV N expressed in *E. coli* and purified as annular ribonucleoprotein complexes composed of 10 N proteins bound to RNA (N-RNA rings) was first obtained in 2009 (Figure 5A) [99]. More recently, the structure of oligomeric N of hMPV, also purified as N-RNA rings, was also obtained [87]. These structures revealed strong structural conservation: N proteins have N- and C-terminal globular domains (N<sub>NTD</sub> and N<sub>CTD</sub>, respectively) separated by a hinge region that forms the RNA-binding groove. Two flexible arms located at the N- and C-terminus of the protein bind to adjacent N protomers and rigidify the structure (Figure 5A).



**Figure 5.** Structure of Pneumovirus N proteins. **(A)** Top (upper panel) and side (lower panel) views of hRSV N-RNA rings composed of 10 N proteins bound to RNA, purified from *E. coli* (PDB: 2WJ8 and 5FVC, respectively). N monomers are represented in ribbons; one N subunit is colored with the N<sub>NTD</sub> in orange, N<sub>CTD</sub> in yellow, and the N- and C-terminal parts in blue and green, respectively. The RNA is represented with the bases in black. N- and C-terminal extremities are indicated. **(B)** Left-handed N-RNA helix model (PDB: 4BKK). N monomers and RNA (black) atoms are shown as surfaces. One N subunit is colored with the N<sub>NTD</sub> in orange, N<sub>CTD</sub> in yellow, and the N- and C-terminal parts in blue and green, respectively. The C-terminal extremity of the N monomer at the top of the helix model is annotated. Created with UCSF ChimeraX [100].

The RNA wraps around the N protein ring in a basic groove, with seven nucleotides contacting each N monomer. The RNA is constrained and twisted by the N proteins, alternating rows of four and three stacked bases that are exposed and buried within the protein groove, respectively. Surprisingly, N-RNA rings, which were considered artifacts of production/purification, were recently found together with NCs in viral particles [101]. This raises the question of the potential role of these oligomers during the viral cycle. Electron microscopy analysis of hRSV NCs expressed in insect cells as well as cryotomography performed on viral particles revealed that these are left-handed helices [102,103]. Although the resolution of the helix was low, an atomic model of a left-handed RSV NC was generated (Figure 5B). These data allowed us to gain information on the interactions between N protomers of successive helix turns, and more importantly, to reveal that the 3' end of the RSV genome is located at the pointed end of the NC. The structure of NC at high resolution still remains to be established to gain information on the mechanism sustaining the encapsidation of the viral genome and those required to allow genome accessibility to the polymerase.

Finally, during viral replication, the neo-synthesized N is maintained monomeric and RNA-free (N<sup>0</sup>) by P, which acts as a chaperone (see Section 7.2). Compared to the oligomeric form, N<sup>0</sup> is characterized by a weak rotation of the N<sub>NTD</sub> relative to the N<sub>CTD</sub> and by the interaction of the N C-arm with the RNA groove, thereby preventing RNA binding.


## 7. N-P Interactions as Targets for New Antiviral Approaches

As previously mentioned, there is still no vaccine nor efficient antivirals against hRSV and hMPV. Most of the molecules under clinical trials target the fusion protein or the enzymatic activities of the L polymerase. However, the emergence of escape mutants upon treatments suggests that the combination of antivirals would be a necessity to prevent/limit

the emergence of resistant viruses. The activity of the RdRp depends on many regulated PPIs. Among those, N-P interactions that are highly specific, of low affinity, and have no counterpart in cells, represent alternative targets for the development of new antivirals against hRSV and hMPV. Of interest, the structural data obtained for these PPIs now allow the rational design of inhibitors.

### 7.1. Interaction of P with NCs and Inhibition

By binding to N, P mediates the attachment of the L protein to the NCs. This interaction was well characterized for hRSV, and was recently shown to be essential for IBs' biogenesis [73]. Using recombinant proteins, it was shown that the nine C-terminal residues of hRSV P are necessary and sufficient for binding to N-RNA rings [89]. More specifically, the C-terminal acidic and hydrophobic residues of P were shown to be critical for this interaction. Using a rational structure-based approach, the domain of hRSV N involved in P<sub>CTD</sub> binding was then identified as N<sub>NTD</sub> [90]. NMR interaction experiments showed that the last 10 C-terminal residues of P were involved in binding to N-RNA rings and N<sub>NTD</sub>, forming fuzzy complexes [83,91]. Residues of N critical for the interaction with P were found in a well-defined pocket composed of hydrophobic residues surrounded by positively charged residues [90]. These results were confirmed by the crystal structure of the N<sub>NTD</sub> domain in the complex with the last two residues of P (P2 peptide in Figure 6) and highlighted the pivotal role of the P C-terminal residue Phe<sup>241</sup>, deeply buried in the N<sub>NTD</sub> pocket [91]. It is noteworthy that this N pocket is accessible at the surface of the modelized helical nucleocapsid [102].



**Figure 6.** X-ray structure of hRSV N protein protomer and of N<sub>NTD</sub> in complex with P2 peptide and M76 compound. (A) An hRSV N protomer taken from the X-ray structure of N-RNA rings (PDB 2WJ8) is represented in ribbons, with the N<sub>NTD</sub> in orange, N<sub>CTD</sub> in yellow, and the N- and C-terminal arms in blue and green, respectively. The residues of N critical for the interaction with P are shown with lateral chains in black. N- and C-terminal extremities are indicated. (B) Zoom into the P2-binding site on N<sub>NTD</sub> (left panel, P2 in cyan) (PDB: 4UCA) and of the M76 compound binding site (right panel, M76 in deep blue) (PDB: 4UCC). The residues of N involved in the interaction with P2 or M76 are indicated. Created with UCSF Chimera [104].

The low affinity of this N-P interaction coupled with the structural characterization of the P binding site on N suggested that small molecules could bind to the pocket of N to impair the P interaction. In silico screening of small compounds was thus performed to identify molecules that could insert into this P binding site. The M76 compound was able to compete in vitro with P for binding to N<sub>NTD</sub> despite its low affinity ( $\mu\text{M}$  range). The crystallographic structure of the N<sub>NTD</sub>-M76 complex revealed that it displayed an optimal charge and shape for N binding (Figure 6B) [91]. However, M76 did not present any antiviral activity on infected cell cultures due to two acidic moieties preventing

cell membrane passage. Further chemical modifications of M76 led to the electrically neutral pH-sensitive prodrug diAM-M76, which was internalized in cells. Although these modifications afforded a molecule with antiviral activity, diAM-M76 displayed a limited activity and important cytotoxicity [91]. Hence, although this approach validated the interest of targeting the P binding pocket of N, further chemical optimization of this compound is required to improve its affinity for N, as well as their cellular delivery and safety.

Other studies confirmed that this N-P interaction represents a potential target to develop antivirals against hRSV. Flavonoids such as hesperetin (Hst) or quercetin were initially shown to inhibit hRSV replication *in vitro* [105]. By coupling experimental and computational approaches, it was recently shown that Hst interacts with N, the aromatic ring of Hst being buried inside the hydrophobic N<sub>NTD</sub> pocket involved in P binding [106], similarly to M76. High-throughput screening of a tailored library also led to the identification of the compound RSV-604 as a specific inhibitor of hRSV replication [107,108]. Further characterization of the mode of action of RSV-604 revealed that this benzodiazepine blocks both *de novo* synthesis of viral RNA and viral infectivity (assembly and release of virions) [109]. However, treatment of hRSV-infected cells with RSV-604 resulted in the emergence of resistant escape mutants, mutations being located in a region of N<sub>NTD</sub> close to the P binding site. Based on these results, the compound EDP-938 has been developed [110]. Compared to RSV-604, EDP-938 displayed improved antiviral activity against hRSV, validated in non-human primates, but escape mutations also occurred on N. As mutations involved in the emergence of resistance concerned residues located close to the P binding site, it is tempting to speculate that these molecules could interfere with the N-P interaction. However, no structural nor experimental data supporting this hypothesis have been reported yet. Finally, a recent study showed that overexpression of P<sub>CTD</sub> in cells inhibits hRSV replication, suggesting that a peptidomimetic approach could be developed to block the P-NC interaction [111].


Until recently, no information was available for the hMPV N-P interaction. Based on the strong structural and functional homologies between hMPV and hRSV N and P proteins, it was expected that N-P interactions could be partially conserved. Using site-directed mutagenesis approaches, coupled with *in vitro* and *in cellula* interaction assays, the last six C-terminal residues of hMPV P protein were shown to be necessary and sufficient for binding to N-RNA rings. Residues of P involved in this interaction, including the last C-terminal residue M<sup>294</sup>, are mostly hydrophobic [112]. Similar to hRSV, residues of N involved in the interaction were found at the surface of N<sub>NTD</sub>, and residues critical for P binding form a pocket mainly composed of hydrophobic residues, surrounded by charged residues [112]. Based on these results, molecular modeling was used to establish a model of binding between the last three C-terminal residues of P and N<sub>NTD</sub>. Altogether, these data confirmed the strong structural homologies between hMPV and hRSV P-N complexes but also highlighted some specificity. Therefore, whereas the hMPV P binding pocket at the N<sub>NTD</sub> surface could also become a target for the rational design of hMPV antivirals, the design of dual inhibitors that could block both hMPV and hRSV N-P interaction is less likely.

## 7.2. The Pneumovirus N<sup>0</sup>-P Complex

The encapsidation process of neosynthesized genome and antigenome by N<sup>0</sup> is an essential step of the viral cycle, the details of which are not yet fully understood. One main issue to gain information on the mechanism involved in the switch from N<sup>0</sup> to N-RNA forms was to isolate and characterize a recombinant monomeric N<sup>0</sup>. Due to the N protein displaying a strong tendency to interact with RNA and to oligomerize, the purification of recombinant N<sup>0</sup> has long been challenging. Different strategies were developed to prevent both RNA interaction and oligomerization of N. Initial approaches consisted in truncation of the N-terminal arm of N to impair N oligomerization [113,114] or substitution of N residues involved in RNA binding [115]. Using co-expression of recombinant mutated

monomeric hRSV N protein with P fragments, the 29 N-terminal residues of P were shown to be sufficient to interact with N<sup>0</sup> [114]. These results confirmed the predictions previously made based on sequence homologies between *Mononegavirales* [116], and the results obtained for its close homolog, the bRSV, showing an interaction between the N-terminus of P and N [117,118]. Moreover, the periodicity of the residues of hRSV P critical for N<sup>0</sup> binding suggested that the stretch spanning residues 11–28 of P could adopt an  $\alpha$ -helical conformation upon binding to N [115].

A major advance was made with the purification of a recombinant chimeric protein corresponding to full-length N fused with the N-terminal domain of P (first 40 residues), which allowed the resolution of the X-ray crystal structure of the hMPV N<sup>0</sup>-P complex (Figure 7) [87]. This structure revealed that the P peptide binds to a hydrophobic surface on N<sub>CTD</sub>. More specifically, residues 12–28 of P form an  $\alpha$ -helix that lies atop N, and the N-terminal residues of P wrap along the N<sub>CTD</sub>. Interestingly, the P peptide binding site on N overlaps with the binding sites of both the N- and C-arms of the N<sub>-i</sub> and N<sub>+i</sub> protomers in the oligomeric form, preventing N self-oligomerization. This structure also revealed that the N<sup>0</sup> form is characterized by a rotation of N<sub>NTD</sub> relatively to N<sub>CTD</sub>, compared to the oligomeric form. Finally, the C-terminal arm of N was shown to fold into the positively charged RNA groove, blocking the binding of RNA.



**Figure 7.** Structural changes involved in the transition from hMPV N<sup>0</sup>-P to oligomeric N-RNA forms. The transition requires the presence of RNA, as indicated at the bottom of the figure. (A) Crystal structure of hMPV N<sup>0</sup>-P<sub>1-28</sub> peptide complex (PDB: 5FVD). (B) Representation of a trimer of N in cartoon representation bound to RNA shown in black sticks (PDB: 5FVC). The black and red arrows symbolize the movement of the N C-arm and the release of P<sub>1-28</sub> peptide, respectively, required for N oligomerization. One N subunit is colored with the N<sub>NTD</sub> in orange, N<sub>CTD</sub> in yellow, and the N- and C-terminal parts in blue and green, respectively. The P<sub>1-28</sub> peptide is in pink. The N- and C-terminal extremities of N and the P peptide are indicated. Created with BioRender.com and UCSF ChimeraX [100].

Although the structure of the hRSV N<sup>0</sup>-P complex has not been solved yet, biochemical and biophysical studies confirmed the strong structural homology with hMPV. First, NMR characterization of hRSV P revealed that residues 12–24 present  $\alpha$ -helical propensity [83]. Co-purification of hRSV N protein deleted of the N-arm (N <sub>$\Delta$ 30</sub>) with 40 residues long peptide of P (P40) determined that the P binding site is located on N<sub>CTD</sub> and that the C-arm of N is critical to prevent RNA binding [114]. Based on the biochemical and biophysical characterization of this N <sub>$\Delta$ 30</sub>-P40 complex, the strong homologies between hRSV and hMPV N and P, and in particular, the strong conservation of key residues involved in the N<sup>0</sup>-P interaction, a structural model of the hRSV N<sup>0</sup>-P complex was proposed [114]. In contrast to N<sup>0</sup>-P complexes of other *Mononegavirales*, such as VSV, Nipah, Ebola, and Marburg viruses or parainfluenza 5 (PIV5), for which the binding of P was shown to be sufficient to maintain N<sup>0</sup> [119–125], these observations demonstrated that the stability of pneumoviruses N<sup>0</sup>-P complexes requires a double lock system depending on P binding and on conformational changes of N (Figure 7).

Besides the identification of the hRSV P region involved in N<sup>0</sup> binding, it was shown that the overexpression of a peptide with the corresponding sequence in cells could block the polymerase activity, giving a proof of concept that targeting the N<sup>0</sup>-P complex might be a way to develop novel antivirals against hRSV [114]. Accumulating data confirmed that the region encompassing residues 12–24 of P has a propensity to adopt an  $\alpha$ -helical conformation that is stabilized upon binding [63,114,115]. Based on this observation, a strategy aiming at specifically targeting the N<sup>0</sup>-P interaction using dominant negative peptide inhibitors that mimic the N-terminus of P was recently developed [126]. These inhibitors were synthesized using the stapled peptide technology that constrains short peptides into  $\alpha$ -helical conformation [127–129]. The presence of staples was shown to increase the potency, proteolytic stability, and cellular permeation of peptides. Of note, such a strategy was used to design peptide inhibitors of the hRSV F protein involved in the virus entry [130,131]. Screening of stapled peptides derived from the N-terminal sequence of P allowed identification of peptides derived from residues 7–30 of P, presenting an antiviral activity in cell culture, with an EC<sub>50</sub> of approximately 10  $\mu$ M [126]. Despite limited antiviral activity in cell cultures, the lead peptide was shown to reduce hRSV infection in vivo in a mouse model [126]. Because the N<sup>0</sup>-P interaction is mediated by a large interaction surface and involves a short  $\alpha$ -helix, the stapled peptide approach is of greatest interest compared to small molecules. It is noteworthy that, given the strong structural homologies between hRSV and hMPV N<sup>0</sup>-P complexes, identification of the best combination of peptide length and stapling for hRSV would facilitate the design of peptides specific to hMPV.

## 8. Conclusions

The recent advances in the structure of the viral proteins associated with the L polymerase of pneumoviruses pave the way for the development of new antiviral strategies. Of particular interest, the PPIs required for the polymerase functioning represent potential targets for the design of new classes of antivirals. Indeed, these viral interactions are highly specific and have no cellular counterparts, suggesting that inhibitors should have limited off-target activity. Furthermore, because these interactions are transient and of low affinity, molecules of higher affinity should efficiently compete with the native mimicked sequence. Among these PPIs, the two modes of N-P interactions, which are now well characterized and relatively conserved between hRSV and hMPV, can be targeted using rational structure-based approaches. As described here, the design of potent inhibitors will depend on the nature of the PPIs: whereas small molecules seem promising to target the P binding site on oligomeric N and N-RNA complexes, such as the helical NCs, small peptides seem more adapted to inhibit the N<sup>0</sup>-P interaction. Similar approaches could be used to target L-P or M2-1-P interactions. It is noteworthy that these antiviral strategies could be applied to other *Mononegavirales*. Given the emergence of resistant escape viruses

upon treatment with both anti-F and anti-L inhibitors, combinations of molecules directed against different viral targets may be required for efficient and long-term treatment.

**Author Contributions:** Writing original draft preparation, H.D., L.G., C.S., and M.G.; writing—review and editing, C.S., I.G., J.-F.E., and M.G.; supervision, M.G.; funding acquisition, C.S., J.-F.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the French Agence Nationale de la Recherche, generic ANR Antibronchio n° ANR-19-CE18-0012-01 and ANR DecRisP n° ANR-19-CE11-0017.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

- Rima, B.; Collins, P.; Easton, A.; Fouchier, R.; Kurath, G.; Lamb, R.A.; Lee, B.; Maisner, A.; Rota, P.; Wang, L.F. Problems of classification in the family Paramyxoviridae. *Arch. Virol.* **2018**, *163*, 1395–1404. [[CrossRef](#)]
- Afonso, C.L.; Amarasinghe, G.K.; Banyai, K.; Bao, Y.; Basler, C.F.; Bavari, S.; Bejerman, N.; Blasdel, K.R.; Briand, F.X.; Briese, T.; et al. Taxonomy of the order Mononegavirales: Update 2016. *Arch. Virol.* **2016**, *161*, 2351–2360. [[CrossRef](#)]
- Rima, B.; Collins, P.; Easton, A.; Fouchier, R.; Kurath, G.; Lamb, R.A.; Lee, B.; Maisner, A.; Rota, P.; Wang, L.; et al. ICTV Virus Taxonomy Profile: Pneumoviridae. *J. Gen. Virol.* **2017**, *98*, 2912–2913. [[CrossRef](#)]
- Hause, B.M.; Padmanabhan, A.; Pedersen, K.; Gidlewski, T. Feral swine virome is dominated by single-stranded DNA viruses and contains a novel Orthopneumovirus which circulates both in feral and domestic swine. *J. Gen. Virol.* **2016**, *97*, 2090–2095. [[CrossRef](#)] [[PubMed](#)]
- Collins, P.L.; Crowe, J.E. Respiratory Syncytial Virus and Metapneumovirus. In *Fields Virology*, 5th ed.; Knipe, D.M., Howley, P.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; pp. 1601–1646.
- Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O'Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. *Lancet* **2010**, *375*, 1545–1555. [[CrossRef](#)]
- Wang, X.; Li, Y.; Deloria-Knoll, M.; Madhi, S.A.; Cohen, C.; Arguelles, V.L.; Basnet, S.; Bassat, Q.; Brooks, W.A.; Echavarría, M.; et al. Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: A systematic review and meta-analysis. *Lancet Glob. Health* **2021**, *9*, e1077–e1087. [[CrossRef](#)]
- van den Hoogen, B.G.; Osterhaus, D.M.; Fouchier, R.A. Clinical impact and diagnosis of human metapneumovirus infection. *Pediatr. Infect. Dis. J.* **2004**, *23* (Suppl. S1), 25–32. [[CrossRef](#)]
- Shi, T.; McAllister, D.A.; O'Brien, K.L.; Simoes, E.A.F.; Madhi, S.A.; Gessner, B.D.; Polack, F.P.; Balsells, E.; Acacio, S.; Aguayo, C.; et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *Lancet* **2017**, *390*, 946–958. [[CrossRef](#)]
- Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. *Lancet* **2019**, *394*, 757–779.
- Phillips, M.; Finelli, L.; Saiman, L.; Wang, C.; Choi, Y.; Patel, J. Respiratory Syncytial Virus-associated Acute Otitis Media in Infants and Children. *J. Pediatric Infect. Dis. Soc.* **2020**, *9*, 544–550. [[CrossRef](#)]
- Shi, T.; Ooi, Y.; Zaw, E.M.; Utjesanovic, N.; Campbell, H.; Cunningham, S.; Bont, L.; Nair, H.; Investigators, R. Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. *J. Infect. Dis.* **2020**, *222* (Suppl. 7), 628–633. [[CrossRef](#)]
- Papenburg, J.; Alghounaim, M. Unraveling the Pneumonia Burden Associated with Human Metapneumovirus Infection. *Clin. Infect. Dis.* **2021**, *72*, 118–120. [[CrossRef](#)]
- van den Hoogen, B.G.; de Jong, J.C.; Groen, J.; Kuiken, T.; de Groot, R.; Fouchier, R.A.; Osterhaus, A.D. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. *Nat. Med.* **2001**, *7*, 719–724. [[CrossRef](#)] [[PubMed](#)]
- de Graaf, M.; Osterhaus, A.; Fouchier, R.A.M.; Holmes, E.C. Evolutionary dynamics of human and avian metapneumoviruses. *J. Gen. Virol.* **2008**, *89*, 2933–2942. [[CrossRef](#)]
- Falsey, A.R.; Hennessey, P.A.; Formica, M.A.; Cox, C.; Walsh, E.E. Respiratory syncytial virus infection in elderly and high-risk adults. *N. Engl. J. Med.* **2005**, *352*, 1749–1759. [[CrossRef](#)] [[PubMed](#)]
- Asner, S.; Stephens, D.; Pedulla, P.; Richardson, S.E.; Robinson, J.; Allen, U. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. *Pediatr. Infect. Dis. J.* **2013**, *32*, 1073–1076. [[CrossRef](#)] [[PubMed](#)]
- Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L.J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA* **2003**, *289*, 179–186. [[CrossRef](#)] [[PubMed](#)]

19. Shah, J.N.; Chemaly, R.F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. *Blood* **2011**, *117*, 2755–2763. [[CrossRef](#)]
20. Uddin, S.; Thomas, M. *Human Metapneumovirus*; StatPearls: Treasure Island, FL, USA, 2021.
21. Cowling, B.J.; Ali, S.T.; Ng, T.W.Y.; Tsang, T.K.; Li, J.C.M.; Fong, M.W.; Liao, Q.; Kwan, M.Y.; Lee, S.L.; Chiu, S.S.; et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: An observational study. *Lancet Public Health* **2020**, *5*, e279–e288. [[CrossRef](#)]
22. Foley, D.A.; Phuong, L.K.; Peplinski, J.; Lim, S.M.; Lee, W.H.; Farhat, A.; Minney-Smith, C.A.; Martin, A.C.; Mace, A.O.; Sikazwe, C.T.; et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. *Arch. Dis. Child.* **2021**, 1–7. [[CrossRef](#)]
23. Agha, R.; Avner, J.R. Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic. *Pediatrics* **2021**, *148*, e2021052089. [[CrossRef](#)] [[PubMed](#)]
24. Ujiiie, M.; Tsuzuki, S.; Nakamoto, T.; Iwamoto, N. Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan. *Emerg. Infect. Dis.* **2021**, *27*, 2969–2970. [[CrossRef](#)]
25. Di Mattia, G.; Nenna, R.; Mancino, E.; Rizzo, V.; Pierangeli, A.; Villani, A.; Midulla, F. During the COVID-19 pandemic where has respiratory syncytial virus gone? *Pediatr. Pulmonol.* **2021**, *56*, 3106–3109. [[CrossRef](#)] [[PubMed](#)]
26. Easton, A.J.; Domachowski, J.B.; Rosenberg, H.F. Animal pneumoviruses: Molecular genetics and pathogenesis. *Clin. Microbiol. Rev* **2004**, *17*, 390–412. [[CrossRef](#)]
27. Valarcher, J.F.; Taylor, G. Bovine respiratory syncytial virus infection. *Vet. Res.* **2007**, *38*, 153–180. [[CrossRef](#)]
28. Giovanardi, D.; Lupini, C.; Pesente, P.; Rossi, G.; Ortali, G.; Catelli, E. Longitudinal field studies of avian metapneumovirus and turkey hemorrhagic enteritis virus in turkeys suffering from colibacillosis associated mortality. *Vet. Res. Commun.* **2014**, *38*, 129–137. [[CrossRef](#)]
29. Makoschey, B.; Berge, A.C. Review on bovine respiratory syncytial virus and bovine parainfluenza—Usual suspects in bovine respiratory disease—A narrative review. *BMC Vet. Res.* **2021**, *17*, 261. [[CrossRef](#)] [[PubMed](#)]
30. Richard, C.A.; Hervet, C.; Menard, D.; Gutsche, I.; Normand, V.; Renois, F.; Meurens, F.; Eleouet, J.F. First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies. *Vet. Res.* **2018**, *49*, 118. [[CrossRef](#)]
31. Ellis, J.A. How efficacious are vaccines against bovine respiratory syncytial virus in cattle? *Vet. Microbiol.* **2017**, *206*, 59–68. [[CrossRef](#)]
32. Valarcher, J.F.; Hagglund, S.; Naslund, K.; Jouneau, L.; Malmstrom, E.; Boulesteix, O.; Pinard, A.; Leguere, D.; Deslis, A.; Gauthier, D.; et al. Single-Shot Vaccines against Bovine Respiratory Syncytial Virus (BRSV): Comparative Evaluation of Long-Term Protection after Immunization in the Presence of BRSV-Specific Maternal Antibodies. *Vaccines* **2021**, *9*, 236. [[CrossRef](#)]
33. Sun, J.; Wei, Y.; Rauf, A.; Zhang, Y.; Ma, Y.; Zhang, X.; Shilo, K.; Yu, Q.; Saif, Y.M.; Lu, X.; et al. Methyltransferase-defective avian metapneumovirus vaccines provide complete protection against challenge with the homologous Colorado strain and the heterologous Minnesota strain. *J. Virol.* **2014**, *88*, 12348–12363. [[CrossRef](#)]
34. Ball, C.; Forrester, A.; Herrmann, A.; Lemiere, S.; Ganapathy, K. Comparative protective immunity provided by live vaccines of Newcastle disease virus or avian metapneumovirus when co-administered alongside classical and variant strains of infectious bronchitis virus in day-old broiler chicks. *Vaccine* **2019**, *37*, 7566–7575. [[CrossRef](#)]
35. Collins, P.L.; Melero, J.A. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. *Virus Res.* **2011**, *162*, 80–99. [[CrossRef](#)] [[PubMed](#)]
36. Cockerill, G.S.; Good, J.A.D.; Mathews, N. State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. *J. Med. Chem.* **2019**, *62*, 3206–3227. [[CrossRef](#)]
37. Detalle, L.; Stohr, T.; Palomo, C.; Piedra, P.A.; Gilbert, B.E.; Mas, V.; Millar, A.; Power, U.F.; Stortelers, C.; Allosery, K.; et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. *Antimicrob. Agents Chemother.* **2015**, *60*, 6–13. [[CrossRef](#)] [[PubMed](#)]
38. Stevens, M.; Rusch, S.; DeVincenzo, J.; Kim, Y.I.; Harrison, L.; Meals, E.A.; Boyers, A.; Fok-Seang, J.; Huntjens, D.; Lounis, N.; et al. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. *J. Infect. Dis.* **2018**, *218*, 748–756. [[CrossRef](#)] [[PubMed](#)]
39. Cockerill, G.S. JNJ-5371678, Defining a Role for Fusion Inhibitors in the Treatment of Respiratory Syncytial Virus. *J. Med. Chem.* **2020**, *63*, 8043–8045. [[CrossRef](#)] [[PubMed](#)]
40. DeVincenzo, J.P.; Whitley, R.J.; Mackman, R.L.; Scaglioni-Weinlich, C.; Harrison, L.; Farrell, E.; McBride, S.; Lambkin-Williams, R.; Jordan, R.; Xin, Y.; et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. *New Engl. J. Med.* **2014**, *371*, 711–722. [[CrossRef](#)]
41. DeVincenzo, J.P.; McClure, M.W.; Symons, J.A.; Fathi, H.; Westland, C.; Chanda, S.; Lambkin-Williams, R.; Smith, P.; Zhang, Q.; Beigelman, L.; et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. *New Engl. J. Med.* **2015**, *373*, 2048–2058. [[CrossRef](#)]
42. Wang, G.; Deval, J.; Hong, J.; Dyatkina, N.; Prhavc, M.; Taylor, J.; Fung, A.; Jin, Z.; Stevens, S.K.; Serebryany, V.; et al. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. *J. Med. Chem.* **2015**, *58*, 1862–1878. [[CrossRef](#)]



43. Chemaly, R.F.; Dadwal, S.S.; Bergeron, A.; Ljungman, P.; Kim, Y.J.; Cheng, G.S.; Pipavath, S.N.; Limaye, A.P.; Blanchard, E.; Winston, D.J.; et al. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. *Clin. Infect. Dis.* **2020**, *71*, 2777–2786. [[CrossRef](#)]
44. Marty, F.M.; Chemaly, R.F.; Mullane, K.M.; Lee, D.G.; Hirsch, H.H.; Small, C.B.; Bergeron, A.; Shoham, S.; Ljungman, P.; Waghmare, A.; et al. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. *Clin. Infect. Dis.* **2020**, *71*, 2787–2795. [[PubMed](#)]
45. Kiss, G.; Holl, J.M.; Williams, G.M.; Alonas, E.; Vanover, D.; Lifland, A.W.; Gudheti, M.; Guerrero-Ferreira, R.C.; Nair, V.; Yi, H.; et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. *J. Virol.* **2014**, *88*, 7602–7617. [[CrossRef](#)]
46. Jeffree, C.E.; Rixon, H.W.; Brown, G.; Aitken, J.; Sugrue, R.J. Distribution of the attachment (G) glycoprotein and GM1 within the envelope of mature respiratory syncytial virus filaments revealed using field emission scanning electron microscopy. *Virology* **2003**, *306*, 254–267. [[CrossRef](#)]
47. Ke, Z.; Dillard, R.S.; Chirkova, T.; Leon, F.; Stobart, C.C.; Hampton, C.M.; Strauss, J.D.; Rajan, D.; Rostad, C.A.; Taylor, J.V.; et al. The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. *Viruses* **2018**, *10*, 446. [[CrossRef](#)]
48. Thornhill, E.M.; Verhoeven, D. Respiratory Syncytial Virus’s Non-structural Proteins: Masters of Interference. *Front. Cell Infect. Microbiol.* **2020**, *10*, 225. [[CrossRef](#)]
49. Sedeyn, K.; Schepens, B.; Saelens, X. Respiratory syncytial virus nonstructural proteins 1 and 2: Exceptional disrupters of innate immune responses. *PLoS Pathog.* **2019**, *15*, e1007984. [[CrossRef](#)]
50. Carter, S.D.; Dent, K.C.; Atkins, E.; Foster, T.L.; Verow, M.; Gorny, P.; Harris, M.; Hiscox, J.A.; Ranson, N.A.; Griffin, S.; et al. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. *FEBS Lett.* **2010**, *584*, 2786–2790. [[CrossRef](#)]
51. Russell, R.F.; McDonald, J.U.; Ivanova, M.; Zhong, Z.; Bukreyev, A.; Tregoning, J.S. Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1beta Responses. *J. Virol.* **2015**, *89*, 8974–8981. [[CrossRef](#)] [[PubMed](#)]
52. Russell, C.D.; Unger, S.A.; Walton, M.; Schwarze, J. The Human Immune Response to Respiratory Syncytial Virus Infection. *Clin. Microbiol. Rev.* **2017**, *30*, 481–502. [[CrossRef](#)]
53. Fearn, R.; Plemper, R.K. Polymerases of paramyxoviruses and pneumoviruses. *Virus Res.* **2017**, *234*, 87–102. [[CrossRef](#)] [[PubMed](#)]
54. Collins, P.L.; Hill, M.G.; Camargo, E.; Grosfeld, H.; Chanock, R.M.; Murphy, B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 11563–11567.
55. Fearn, R.; Collins, P.L. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. *J. Virol.* **1999**, *73*, 5852–5864. [[CrossRef](#)]
56. Buchholz, U.J.; Biacchesi, S.; Pham, Q.N.; Tran, K.C.; Yang, L.; Luongo, C.L.; Skiadopoulos, M.H.; Murphy, B.R.; Collins, P.L. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: Effects on RNA synthesis, attenuation, and immunogenicity. *J. Virol.* **2005**, *79*, 6588–6597. [[CrossRef](#)] [[PubMed](#)]
57. Rincheval, V.; Lelek, M.; Gault, E.; Bouillier, C.; Sitterlin, D.; Blouquit-Laye, S.; Galloux, M.; Zimmer, C.; Eleouet, J.F.; Rameix-Welti, M.A. Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus. *Nat. Commun.* **2017**, *8*, 563. [[CrossRef](#)] [[PubMed](#)]
58. Dolnik, O.; Gerresheim, G.K.; Biedenkopf, N. New Perspectives on the Biogenesis of Viral Inclusion Bodies in Negative-Sense RNA Virus Infections. *Cells* **2021**, *10*, 1460. [[CrossRef](#)]
59. Lopez, N.; Camporeale, G.; Salgueiro, M.; Borkosky, S.S.; Visentin, A.; Peralta-Martinez, R.; Loureiro, M.E.; de Prat-Gay, G. Deconstructing virus condensation. *PLoS Pathog.* **2021**, *17*, e1009926. [[CrossRef](#)]
60. Garcia, J.; Garcia-Barreno, B.; Vivo, A.; Melero, J.A. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: Formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein. *Virology* **1993**, *195*, 243–247. [[CrossRef](#)]
61. Derdowski, A.; Peters, T.R.; Glover, N.; Qian, R.; Utley, T.J.; Burnett, A.; Williams, J.V.; Spearman, P.; Crowe, J.E. Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation. *J. Gen. Virol.* **2008**, *89*, 2698–2708. [[CrossRef](#)]
62. Weber, E.; Humbert, B.; Streckert, H.J.; Werchau, H. Nonstructural protein 2 (NS2) of respiratory syncytial virus (RSV) detected by an antipeptide serum. *Respiration* **1995**, *62*, 27–33. [[CrossRef](#)] [[PubMed](#)]
63. Ghildyal, R.; Mills, J.; Murray, M.; Vardaxis, N.; Meanger, J. Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. *J. Gen. Virol.* **2002**, *83*, 753–757. [[CrossRef](#)]
64. Bajorek, M.; Galloux, M.; Richard, C.A.; Szekely, O.; Rosenzweig, R.; Sizun, C.; Eleouet, J.F. Tetramerization of Phosphoprotein is Essential for Respiratory Syncytial Virus Budding while its N Terminal Region Mediates Direct Interactions with the Matrix Protein. *J. Virol.* **2021**, *95*, e02217-20. [[CrossRef](#)]

65. Richard, C.A.; Rincheval, V.; Lassoued, S.; Fix, J.; Cardone, C.; Esneau, C.; Nekhai, S.; Galloux, M.; Rameix-Welti, M.A.; Sizun, C.; et al. RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription. *PLoS Pathog.* **2018**, *14*, e1006920. [[CrossRef](#)] [[PubMed](#)]
66. Fricke, J.; Koo, L.Y.; Brown, C.R.; Collins, P.L. p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly. *J. Virol.* **2013**, *87*, 1333–1347. [[CrossRef](#)]
67. Lifland, A.W.; Jung, J.; Alonas, E.; Zurla, C.; Crowe, J.E., Jr.; Santangelo, P.J. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. *J. Virol.* **2012**, *86*, 8245–8258. [[CrossRef](#)]
68. Jobe, F.; Simpson, J.; Hawes, P.; Guzman, E.; Bailey, D. Respiratory Syncytial Virus Sequesters NF-kappaB Subunit p65 to Cytoplasmic Inclusion Bodies To Inhibit Innate Immune Signaling. *J. Virol.* **2020**, *94*, e01380-20. [[CrossRef](#)] [[PubMed](#)]
69. Gilman, M.S.A.; Liu, C.; Fung, A.; Behera, I.; Jordan, P.; Rigaux, P.; Ysebaert, N.; Tcherniuk, S.; Sourimant, J.; Eleouet, J.F.; et al. Structure of the Respiratory Syncytial Virus Polymerase Complex. *Cell* **2019**, *179*, 193–204 e14. [[CrossRef](#)] [[PubMed](#)]
70. Pan, J.; Qian, X.; Lattmann, S.; El Sahili, A.; Yeo, T.H.; Jia, H.; Cressey, T.; Ludeke, B.; Noton, S.; Kalocsay, M.; et al. Structure of the human metapneumovirus polymerase phosphoprotein complex. *Nature* **2020**, *577*, 275–279. [[CrossRef](#)]
71. Sutto-Ortiz, P.; Tcherniuk, S.; Ysebaert, N.; Abeywickrema, P.; Noel, M.; Decombe, A.; Debart, F.; Vasseur, J.J.; Canard, B.; Roymans, D.; et al. The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2'-O-methylation. *PLoS Pathog.* **2021**, *17*, e1009562. [[CrossRef](#)]
72. Garcia, J.; Garcia-Barreno, B.; Martinez, I.; Melero, J.A. Mapping of monoclonal antibody epitopes of the human respiratory syncytial virus p protein. *Virology* **1993**, *195*, 239–242. [[CrossRef](#)] [[PubMed](#)]
73. Galloux, M.; Risso-Ballester, J.; Richard, C.A.; Fix, J.; Rameix-Welti, M.A.; Eleouet, J.F. Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro. *mBio* **2020**, *11*, e01202-20. [[CrossRef](#)] [[PubMed](#)]
74. Banani, S.F.; Lee, H.O.; Hyman, A.A.; Rosen, M.K. Biomolecular condensates: Organizers of cellular biochemistry. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 285–298. [[CrossRef](#)]
75. Elbaum-Garfinkle, S.; Kim, Y.; Szczepaniak, K.; Chen, C.C.; Eckmann, C.R.; Myong, S.; Brangwynne, C.P. The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 7189–7194. [[CrossRef](#)] [[PubMed](#)]
76. Nott, T.J.; Petsalaki, E.; Farber, P.; Jervis, D.; Fussner, E.; Plochowitz, A.; Craggs, T.D.; Bazett-Jones, D.P.; Pawson, T.; Forman-Kay, J.D.; et al. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. *Mol. Cell* **2015**, *57*, 936–947. [[CrossRef](#)] [[PubMed](#)]
77. Castagne, N.; Barbier, A.; Bernard, J.; Rezaei, H.; Huet, J.C.; Henry, C.; Da Costa, B.; Eleouet, J.F. Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain. *J. Gen. Virol.* **2004**, *85*, 1643–1653. [[CrossRef](#)]
78. Llorente, M.T.; Garcia-Barreno, B.; Calero, M.; Camafeita, E.; Lopez, J.A.; Longhi, S.; Ferron, F.; Varela, P.F.; Melero, J.A. Structural analysis of the human respiratory syncytial virus phosphoprotein: Characterization of an alpha-helical domain involved in oligomerization. *J. Gen. Virol.* **2006**, *87*, 159–169. [[CrossRef](#)]
79. Llorente, M.T.; Taylor, I.A.; Lopez-Vinas, E.; Gomez-Puertas, P.; Calder, L.J.; Garcia-Barreno, B.; Melero, J.A. Structural properties of the human respiratory syncytial virus P protein: Evidence for an elongated homotetrameric molecule that is the smallest orthologue within the family of paramyxovirus polymerase cofactors. *Proteins* **2008**, *72*, 946–958. [[CrossRef](#)]
80. Simabuco, F.M.; Asara, J.M.; Guerrero, M.C.; Libermann, T.A.; Zerbini, L.F.; Ventura, A.M. Structural analysis of human respiratory syncytial virus p protein: Identification of intrinsically disordered domains. *Braz. J. Microbiol.* **2011**, *42*, 340–345. [[CrossRef](#)]
81. Renner, M.; Paesen, G.C.; Grison, C.M.; Granier, S.; Grimes, J.M.; Leyrat, C. Structural dissection of human metapneumovirus phosphoprotein using small angle x-ray scattering. *Sci. Rep.* **2017**, *7*, 14865. [[CrossRef](#)]
82. Di Tommaso, P.; Moretti, S.; Xenarios, I.; Orobittg, M.; Montanyola, A.; Chang, J.M.; Taly, J.F.; Notredame, C. T-Coffee: A web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. *Nucleic Acids Res.* **2011**, *39*, W13–W17. [[CrossRef](#)] [[PubMed](#)]
83. Pereira, N.; Cardone, C.; Lassoued, S.; Galloux, M.; Fix, J.; Assrir, N.; Lescop, E.; Bontems, F.; Eleouet, J.F.; Sizun, C. New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners. *J. Biol. Chem.* **2017**, *292*, 2120–2131. [[CrossRef](#)]
84. Cardone, C.; Caseau, C.M.; Bardiaux, B.; Thureau, A.; Galloux, M.; Bajorek, M.; Eleouet, J.F.; Litaudon, M.; Bontems, F.; Sizun, C. A Structural and Dynamic Analysis of the Partially Disordered Polymerase-Binding Domain in RSV Phosphoprotein. *Biomolecules* **2021**, *11*, 1225. [[CrossRef](#)]
85. Cardone, C.; Caseau, C.M.; Pereira, N.; Sizun, C. Pneumoviral Phosphoprotein, a Multidomain Adaptor-Like Protein of Apparent Low Structural Complexity and High Conformational Versatility. *Int. J. Mol. Sci.* **2021**, *22*, 1537. [[CrossRef](#)]
86. Esperante, S.A.; Paris, G.; de Prat-Gay, G. Modular unfolding and dissociation of the human respiratory syncytial virus phosphoprotein p and its interaction with the m(2-1) antiterminator: A singular tetramer-tetramer interface arrangement. *Biochemistry* **2012**, *51*, 8100–8110. [[CrossRef](#)] [[PubMed](#)]
87. Renner, M.; Bertinelli, M.; Leyrat, C.; Paesen, G.C.; Saraiva de Oliveira, L.F.; Huisken, J.T.; Grimes, J.M. Nucleocapsid assembly in pneumoviruses is regulated by conformational switching of the N protein. *eLife* **2016**, *5*, e12627. [[CrossRef](#)] [[PubMed](#)]

88. Selvaraj, M.; Yegambaram, K.; Todd, E.; Richard, C.A.; Dods, R.L.; Pangratiou, G.M.; Trinh, C.H.; Moul, S.L.; Murphy, J.C.; Mankouri, J.; et al. The Structure of the Human Respiratory Syncytial Virus M2-1 Protein Bound to the Interaction Domain of the Phosphoprotein P Defines the Orientation of the Complex. *mBio* **2018**, *9*, e01554-18. [[CrossRef](#)] [[PubMed](#)]
89. Tran, T.L.; Castagne, N.; Bhella, D.; Varela, P.F.; Bernard, J.; Chilmonczyk, S.; Berkenkamp, S.; Benhamo, V.; Grznarova, K.; Grosclaude, J.; et al. The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. *J. Gen. Virol.* **2007**, *88*, 196–206. [[CrossRef](#)]
90. Galloux, M.; Tarus, B.; Blazevic, I.; Fix, J.; Duquerroy, S.; Eleouet, J.F. Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. *J. Virol.* **2012**, *86*, 8375–8387. [[CrossRef](#)] [[PubMed](#)]
91. Ouizougoun-Oubari, M.; Pereira, N.; Tarus, B.; Galloux, M.; Lassoued, S.; Fix, J.; Tortorici, M.A.; Hoos, S.; Baron, B.; England, P.; et al. A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus. *J. Virol.* **2015**, *89*, 11129–11143. [[CrossRef](#)]
92. Navarro, J.; Lopez-Otin, C.; Villanueva, N. Location of phosphorylated residues in human respiratory syncytial virus phosphoprotein. *J. Gen. Virol.* **1991**, *72*, 1455–1459. [[CrossRef](#)]
93. Asenjo, A.; Rodriguez, L.; Villanueva, N. Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: A possible role for serine 54. *J. Gen. Virol.* **2005**, *86*, 1109–1120. [[CrossRef](#)]
94. Mazumder, B.; Barik, S. Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: Transdominant negative phenotype of phosphorylation-defective P mutants. *Virology* **1994**, *205*, 104–111. [[CrossRef](#)] [[PubMed](#)]
95. Villanueva, N.; Hardy, R.; Asenjo, A.; Yu, Q.; Wertz, G. The bulk of the phosphorylation of human respiratory syncytial virus phosphoprotein is not essential but modulates viral RNA transcription and replication. *J. Gen. Virol.* **2000**, *81*, 129–133. [[CrossRef](#)]
96. Lu, B.; Ma, C.H.; Brazas, R.; Jin, H. The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. *J. Virol.* **2002**, *76*, 10776–10784. [[CrossRef](#)] [[PubMed](#)]
97. Asenjo, A.; Gonzalez-Armas, J.C.; Villanueva, N. Phosphorylation of human respiratory syncytial virus P protein at serine 54 regulates viral uncoating. *Virology* **2008**, *380*, 26–33. [[CrossRef](#)]
98. Shapiro, A.B.; Gao, N.; O’Connell, N.; Hu, J.; Thresher, J.; Gu, R.F.; Overman, R.; Hardern, I.M.; Sproat, G.G. Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid protein. *Virol. J.* **2014**, *11*, 191. [[CrossRef](#)]
99. Tawar, R.G.; Duquerroy, S.; Vonrhein, C.; Varela, P.F.; Damier-Piolle, L.; Castagne, N.; MacLellan, K.; Bedouelle, H.; Bricogne, G.; Bhella, D.; et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. *Science* **2009**, *326*, 1279–1283. [[CrossRef](#)]
100. Goddard, T.D.; Huang, C.C.; Meng, E.C.; Pettersen, E.F.; Couch, G.S.; Morris, J.H.; Ferrin, T.E. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* **2018**, *27*, 14–25. [[CrossRef](#)] [[PubMed](#)]
101. Conley, M.J.; Short, J.M.; Hutchings, J.; Burns, A.M.; Streetley, J.; Bakker, S.E.; Jaffery, H.; Stewart, M.; Power, J.; Zanetti, G.; et al. Helical Ordering of Envelope Associated Proteins and Glycoproteins in Respiratory Syncytial Virus Filamentous Virions. *bioRxiv* **2021**. [[CrossRef](#)]
102. Bakker, S.E.; Duquerroy, S.; Galloux, M.; Loney, C.; Conner, E.; Eleouet, J.F.; Rey, F.A.; Bhella, D. The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. *J. Gen. Virol.* **2013**, *94*, 1734–1738. [[CrossRef](#)]
103. Liljeroos, L.; Krzyzaniak, M.A.; Helenius, A.; Butcher, S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 11133–11138. [[CrossRef](#)]
104. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612. [[CrossRef](#)]
105. Kaul, T.N.; Middleton, E., Jr.; Ogra, P.L. Antiviral effect of flavonoids on human viruses. *J. Med. Virol.* **1985**, *15*, 71–79. [[CrossRef](#)]
106. Sa, J.M.; Piloto, J.V.; Cilli, E.M.; Tasic, L.; Fossey, M.A.; Almeida, F.C.L.; Souza, F.P.; Caruso, I.P. Hesperetin targets the hydrophobic pocket of the nucleoprotein/phosphoprotein binding site of human respiratory syncytial virus. *J. Biomol. Struct. Dyn.* **2020**, *20*, 1–13. [[CrossRef](#)]
107. Chapman, J.; Abbott, E.; Alber, D.G.; Baxter, R.C.; Bithell, S.K.; Henderson, E.A.; Carter, M.C.; Chambers, P.; Chubb, A.; Cockerill, G.S.; et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. *Antimicrob. Agents Chemother.* **2007**, *51*, 3346–3353. [[CrossRef](#)] [[PubMed](#)]
108. Henderson, E.A.; Alber, D.G.; Baxter, R.C.; Bithell, S.K.; Budworth, J.; Carter, M.C.; Chubb, A.; Cockerill, G.S.; Dowdell, V.C.; Fraser, I.J.; et al. 14-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. *J. Med. Chem.* **2007**, *50*, 1685–1692. [[CrossRef](#)]
109. Challa, S.; Scott, A.D.; Yuzhakov, O.; Zhou, Y.; Tiong-Yip, C.L.; Gao, N.; Thresher, J.; Yu, Q. Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604. *Antimicrob. Agents Chemother.* **2015**, *59*, 1080–1087. [[CrossRef](#)]
110. Rhodin, M.H.J.; McAllister, N.V.; Castillo, J.; Noton, S.L.; Fearn, R.; Kim, I.J.; Yu, J.M.; Blaisdell, T.P.; Panarese, J.; Shook, B.C.; et al. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. *PLoS Pathog.* **2021**, *17*, e1009428. [[CrossRef](#)] [[PubMed](#)]

111. Hara, K.; Yaita, K.; Khamrin, P.; Kumthip, K.; Kashiwagi, T.; Eleouet, J.F.; Rameix-Welti, M.A.; Watanabe, H. A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein. *J. Gen. Virol.* **2020**, *101*, 21–32. [[CrossRef](#)]
112. Decool, H.; Bardiaux, B.; Checa Ruano, L.; Sperandio, O.; Fix, J.; Gutsche, I.; Richard, C.A.; Bajorek, M.; Eleouet, J.F.; Galloux, M. Characterization of the interaction domains between the phosphoprotein and the nucleoprotein of human Metapneumovirus. *J. Virol.* **2021**, JVI0090921. [[CrossRef](#)] [[PubMed](#)]
113. El Omari, K.; Scott, K.; Dhaliwal, B.; Ren, J.; Abrescia, N.G.A.; Budworth, J.; Lockyer, M.; Powell, K.L.; Hawkins, A.R.; Stammers, D.K. Crystallization and preliminary X-ray analysis of the human respiratory syncytial virus nucleocapsid protein. *Acta Crystallogr. Sect. F-Struct. Biol. Cryst. Comm.* **2008**, *64*, 1019–1023. [[CrossRef](#)]
114. Esneau, C.; Raynal, B.; Roblin, P.; Brule, S.; Richard, C.A.; Fix, J.; Eleouet, J.F.; Galloux, M. Biochemical characterization of the respiratory syncytial virus N(0)-P complex in solution. *J. Biol. Chem.* **2019**, *294*, 3647–3660. [[CrossRef](#)] [[PubMed](#)]
115. Galloux, M.; Gabiane, G.; Sourimant, J.; Richard, C.A.; England, P.; Moudjou, M.; Aumont-Nicaise, M.; Fix, J.; Rameix-Welti, M.A.; Eleouet, J.F. Identification and Characterization of the Binding Site of the Respiratory Syncytial Virus Phosphoprotein to RNA-Free Nucleoprotein. *J. Virol.* **2015**, *89*, 3484–3496. [[CrossRef](#)] [[PubMed](#)]
116. Karlin, D.; Belshaw, R. Detecting remote sequence homology in disordered proteins: Discovery of conserved motifs in the N-termini of Mononegavirales phosphoproteins. *PLoS ONE* **2012**, *7*, e31719.
117. Mallipeddi, S.K.; Lupiani, B.; Samal, S.K. Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system. *J. Gen. Virol.* **1996**, *77*, 1019–1023. [[CrossRef](#)] [[PubMed](#)]
118. Khattar, S.K.; Yunus, A.S.; Samal, S.K. Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. *J. Gen. Virol.* **2001**, *82*, 775–779. [[CrossRef](#)]
119. Jamin, M.; Yabukarski, F. Nonsegmented Negative-Sense RNA Viruses-Structural Data Bring New Insights Into Nucleocapsid Assembly. *Adv. Virus Res.* **2017**, *97*, 143–185.
120. Leyrat, C.; Yabukarski, F.; Tarbouriech, N.; Ribeiro, E.A., Jr.; Jensen, M.R.; Blackledge, M.; Ruigrok, R.W.; Jamin, M. Structure of the vesicular stomatitis virus N(0)-P complex. *PLoS Pathog.* **2011**, *7*, e1002248. [[CrossRef](#)]
121. Yabukarski, F.; Lawrence, P.; Tarbouriech, N.; Bourhis, J.M.; Delaforge, E.; Jensen, M.R.; Ruigrok, R.W.; Blackledge, M.; Volchkov, V.; Jamin, M. Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone. *Nat. Struct. Mol. Biol.* **2014**, *21*, 754–759. [[CrossRef](#)]
122. Guryanov, S.G.; Liljeroos, L.; Kasaragod, P.; Kajander, T.; Butcher, S.J. Crystal Structure of the Measles Virus Nucleoprotein Core in Complex with an N-Terminal Region of Phosphoprotein. *J. Virol.* **2015**, *90*, 2849–2857. [[CrossRef](#)]
123. Kirchdoerfer, R.N.; Abelson, D.M.; Li, S.; Wood, M.R.; Saphire, E.O. Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex. *Cell Rep.* **2015**, *12*, 140–149. [[CrossRef](#)]
124. Zhu, T.; Song, H.; Peng, R.; Shi, Y.; Qi, J.; Gao, G.F. Crystal Structure of the Marburg Virus Nucleoprotein Core Domain Chaperoned by a VP35 Peptide Reveals a Conserved Drug Target for Filovirus. *J. Virol.* **2017**, *91*, e00996-17. [[CrossRef](#)]
125. Aggarwal, M.; Leser, G.P.; Kors, C.A.; Lamb, R.A. Structure of the Paramyxovirus Parainfluenza Virus 5 Nucleoprotein in Complex with an Amino-Terminal Peptide of the Phosphoprotein. *J. Virol.* **2018**, *92*, e01304-17. [[CrossRef](#)] [[PubMed](#)]
126. Galloux, M.; Gsponer, N.; Gaillard, V.; Fenner, B.; Larcher, T.; Vilotte, M.; Riviere, J.; Richard, C.A.; Eleouet, J.F.; Le Goffic, R.; et al. Targeting the Respiratory Syncytial Virus N-0-P Complex with Constrained alpha-Helical Peptides in Cells and Mice. *Antimicrob. Agents Chemother.* **2020**, *64*, e00717-20. [[CrossRef](#)] [[PubMed](#)]
127. Verdine, G.L.; Hilinski, G.J. Stapled peptides for intracellular drug targets. *Methods Enzymol.* **2012**, *503*, 3–33.
128. Kim, Y.W.; Grossmann, T.N.; Verdine, G.L. Synthesis of all-hydrocarbon stapled alpha-helical peptides by ring-closing olefin metathesis. *Nat. Protoc.* **2011**, *6*, 761–771. [[CrossRef](#)]
129. Bird, G.H.; Madani, N.; Perry, A.F.; Princiotta, A.M.; Supko, J.G.; He, X.; Gavathiotis, E.; Sodroski, J.G.; Walensky, L.D. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 14093–14098. [[CrossRef](#)] [[PubMed](#)]
130. Bird, G.H.; Boyapalle, S.; Wong, T.; Opoku-Nsiah, K.; Bedi, R.; Crannell, W.C.; Perry, A.F.; Nguyen, H.; Sampayo, V.; Devareddy, A.; et al. Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. *J. Clin. Investig.* **2014**, *124*, 2113–2124. [[CrossRef](#)]
131. Gaillard, V.; Galloux, M.; Garcin, D.; Eleouet, J.F.; Le Goffic, R.; Larcher, T.; Rameix-Welti, M.A.; Boukadiri, A.; Heritier, J.; Segura, J.M.; et al. A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading. *Antimicrob. Agents Chemother.* **2017**, *61*, e02241-16. [[CrossRef](#)]